US2013195903A1PendingUtilityA1

Compositions for use in the treatment of chronic obstructive pulmonary diseases and asthma

55
Assignee: RES & TECHNOLOGY CORP INDIANA UNIVERSITYPriority: Apr 22, 2009Filed: Mar 12, 2013Published: Aug 1, 2013
Est. expiryApr 22, 2029(~2.7 yrs left)· nominal 20-yr term from priority
Inventors:David Wilkes
A61P 37/02A61P 43/00A61K 9/0019G01N 2800/56G01N 2800/122G01N 2800/50G01N 2333/78G01N 2800/52A61K 9/0073G01N 33/6854A61P 11/00A61P 11/06A61K 39/0008A61K 38/39A61K 9/0053A61P 11/08
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides compounds and methods for treating or preventing pulmonary diseases include COPD and asthma. In particular, the present invention provides for compounds comprising type V collagen, or tolerizing fragments thereof, for the treatment of COPD and asthma.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A composition for treating chronic obstructive pulmonary disease in a COPD patient comprising a therapeutically effective amount of type V collagen, or a tolerogenic fragment thereof. 
     
     
         2 . The composition of  claim 1  wherein the COPD patient has emphysema or chronic obstructive bronchitis. 
     
     
         3 . The composition of  claim 1  wherein the type V collagen or tolerogenic fragment thereof is prepared for oral administration. 
     
     
         4 . The composition of  claim 3  comprising between 0.1 mg and 0.5 mg of type V collagen. 
     
     
         5 . The composition of  claim 1  wherein the type V collagen or tolerogenic fragment thereof is prepared for intravenous administration, intrapulmonary instillation, administration by inhalation, or for intramuscular administration. 
     
     
         6 . The composition of  claim 1 , further comprising a bronchodilator or for use in conjunction with a bronchodilator. 
     
     
         7 . The composition of  claim 1  further comprising a corticosteroid or for use in conjunction with a corticosteroid. 
     
     
         8 . A composition for treating asthma comprising a therapeutically effective amount of type V collagen, or a tolerogenic fragment thereof. 
     
     
         9 . The composition of  claim 8  wherein the type V collagen or tolerogenic fragment thereof is prepared for intravenous administration, intrapulmonary instillation, administration by inhalation, or for intramuscular administration. 
     
     
         10 . The composition of  claim 9  wherein the type V collagen is administered at a dose of between 0.1 mg and 0.5 mg. 
     
     
         11 . The composition of  claim 8  further comprising a corticosteroid or for use in conjunction with a corticosteroid. 
     
     
         12 . The composition of  claim 8  further comprising a bronchodilator or for use in conjunction with a bronchodilator. 
     
     
         13 . The composition of  claim 8  further comprising a leukotriene modifier or for use in conjunction with a leukotriene modifier. 
     
     
         14 . A composition for preventing the development of chronic obstructive pulmonary disease in a subject at risk for developing chronic obstructive pulmonary disease comprising a therapeutically effective amount of type V collagen, or a tolerogenic fragment thereof. 
     
     
         15 . The composition of  claim 14  wherein the type V collagen or tolerogenic fragment thereof is administered orally. 
     
     
         16 . The composition of  claim 15  wherein the type V collagen is administered at a dose of between 0.1 mg and 0.5 mg. 
     
     
         17 . The composition of  claim 14  wherein the type V collagen or tolerogenic fragment thereof is prepared for intravenous administration, intrapulmonary instillation, administration by inhalation, or for intramuscular administration. 
     
     
         18 . A composition for preventing the development or worsening of asthma in a subject at risk for developing asthma comprising a therapeutically effective amount of type V collagen, or a tolerogenic fragment thereof. 
     
     
         19 . The composition of  claim 18  wherein the type V collagen or tolerogenic fragment thereof is administered orally. 
     
     
         20 . The composition of  claim 19  wherein the type V collagen is administered at a dose of between 0.1 mg and 0.5 mg. 
     
     
         21 . The composition of  claim 18  wherein the type V collagen or tolerogenic fragment thereof is prepared for intravenous administration, intrapulmonary instillation, administration by inhalation, or for intramuscular administration. 
     
     
         22 . A method for identifying a COPD or asthma patient as a candidate for collagen V tolerance therapy comprising,
 contacting at least a portion of a sample of blood from the patient with collagen V or an antigenic fragment thereof; and   measuring the level of antibodies that bind to the collagen V or antigenic fragment thereof;   wherein the presence of antibodies specifically bound to the collagen V is indicative that the COPD or asthma patient would benefit from collagen V tolerance therapy.   
     
     
         23 . The method of  claim 22  wherein the collagen V or antigenic fragment thereof is conjugated to a bead. 
     
     
         24 . The method of  claim 22  wherein the measuring comprises
 contacting the antibodies that specifically bind to the collagen V or antigenic fragment thereof with a fluorescently labeled anti-IgG antibody; and 
 detecting by flow cytometry the amount of fluorescently labeled anti-IgG antibody bound to the antibodies bound to the collagen V. 
 
     
     
         25 . A method for identifying an individual at risk for developing COPD or asthma, comprising:
 contacting at least a portion of a sample of blood from the individual with collagen V or an antigenic fragment thereof; and   measuring the level of antibodies that bind to the collagen V or an antigenic fragment thereof;   wherein the presence of antibodies that specifically bind to the collagen V is associated with a higher risk than would be expected in an individual with no antibodies that bind to the collagen V.   
     
     
         26 . The method of  claim 25  wherein the collagen V or antigenic fragment thereof is conjugated to a bead. 
     
     
         27 . The method of  claim 25  wherein the measuring comprises
 contacting the antibodies that bind to the collagen V or antigenic fragment thereof with a fluorescently labeled anti-IgG antibody; and 
 detecting by flow cytometry the amount of fluorescently labeled anti-IgG antibody bound to the antibodies bound to the collagen V. 
 
     
     
         28 . The method of  claim 24  or  27  wherein the anti-IgG antibody detects all IgG subtypes. 
     
     
         29 . The method of  claim 24  or  27  wherein the anti-IgG antibody specifically detects the IgG1 subtype. 
     
     
         30 . The method of  claim 24  or  27  wherein the anti-IgG antibody specifically detects the IgG2 subtype. 
     
     
         31 . The method of  claim 24  or  27  wherein the anti-IgG antibody specifically detects the IgG3 subtype. 
     
     
         32 . The method of  claim 24  or  27  wherein the anti-IgG antibody specifically detects the IgG4 subtype. 
     
     
         33 . A method for monitoring the progression of COPD in an individual comprising,
 contacting at least a portion of a first sample of blood from the individual with collagen V or an antigenic fragment thereof;   measuring the level of antibodies that specifically bind to the collagen V or antigenic fragment thereof in the first sample of blood;   contacting at least a portion of a second sample of blood from the individual taken at a later time point, with collagen V or an antigenic fragment thereof;   measuring the level of antibodies that specifically bind to the collagen V or antigenic fragment thereof in the second sample of blood; and   comparing the level of antibodies that specifically bind to the collagen V or antigenic fragment thereof in the second sample of blood to the level of antibodies that specifically bind to the collagen V or antigenic fragment thereof in the first sample of blood;   wherein an increase in the level of antibodies bound to the collagen V in the second sample as compared to the first sample is indicative of worsening of COPD and a decrease in the level of antibodies bound to the collagen V in the second sample as compared to the first sample is indicative of amelioration of COPD.   
     
     
         34 . The method of  claim 33  wherein the collagen V or antigenic fragment thereof is conjugated to a bead. 
     
     
         35 . The method of  claim 33  wherein the measuring comprises
 contacting the antibodies that bind to the collagen V or antigenic fragment thereof with a fluorescently labeled anti-IgG antibody; and 
 detecting by flow cytometry the amount of fluorescently labeled anti-IgG antibody bound to the antibodies bound to the collagen V. 
 
     
     
         36 . A method for monitoring the progression of asthma in an individual comprising,
 contacting at least a portion of a first sample of blood from the individual with collagen V or an antigenic fragment thereof;   measuring the level of antibodies that bind to the collagen V or antigenic fragment thereof in the first sample of blood;   contacting at least a portion of a second sample of blood from the individual taken at a later time point, with collagen V or an antigenic fragment thereof;   measuring the level of antibodies that bind to the collagen V or antigenic fragment thereof in the second sample of blood; and   comparing the level of antibodies that bind to the collagen V or antigenic fragment thereof in the second sample of blood to the level of antibodies that bind to the collagen V or antigenic fragment thereof in the first sample of blood;   wherein an increase in the level of antibodies bound to the collagen V in the second sample as compared to the first sample is indicative of worsening of asthma and a decrease in the level of antibodies bound to the collagen V in the second sample as compared to the first sample is indicative of amelioration of asthma.   
     
     
         37 . The method of  claim 36  wherein the collagen V or antigenic fragment thereof is conjugated to a bead. 
     
     
         38 . The method of  claim 37  wherein the measuring comprises
 contacting the antibodies that bind to the collagen V or antigenic fragment thereof with a fluorescently labeled anti-IgG antibody; and 
 detecting by flow cytometry the amount of fluorescently labeled anti-IgG antibody bound to the antibodies bound to the collagen V. 
 
     
     
         39 . The method of  claim 35  or  38  wherein the anti-IgG antibody detects all IgG subtypes. 
     
     
         40 . The method of  claim 35  or  38  wherein the anti-IgG antibody specifically detects the IgG1 subtype. 
     
     
         41 . The method of  claim 35  or  38  wherein the anti-IgG antibody specifically detects the IgG2 subtype. 
     
     
         42 . The method of  claim 35  or  38  wherein the anti-IgG antibody specifically detects the IgG3 subtype. 
     
     
         43 . The method of  claim 35  or  38  wherein the anti-IgG antibody specifically detects the IgG4 subtype.

Join the waitlist — get patent alerts

Track US2013195903A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.